Factors predicting ureteral stenosis after transurethral resection of the ureteral orifice: a two-center, retrospective clinical study Authors: Ekrem Güner, Emre Şam, Ali Emre Fakir, Mustafa Sacit Güneren, Abdullah Turan, Hüseyin Koçakgöl, Ahmet Emre Cinislioğlu, Fatih Akkaş Published: 2025 ABSTRACT PurposeWe aimed to evaluate the factors predictive of ureteral stenosis after orifice resection and to determine whether ureteral stenting is effective in preventing it.MethodsThe data of patients who underwent transurethral resection of bladder tumor (TUR-BT) in the clinics of two tertiary centers between June 2020 and January 2024 were retrospectively reviewed. Patients who underwent orifice resection due to tumor involvement of the ureteral orifice or too close to it were included in the study. During follow-up, cystoscopy ± diagnostic ureterorenoscopy was performed in patients with hydronephrosis. Ureteral stenosis was defined as a narrowing that precluded the passage of the ureterorenoscope and where no tumoral lesion was detected at the orifice site.ResultsA total of 96 patients were included in the study. A D-J stent was inserted in 49 (51%) of the patients following TUR-BT. At a median follow-up of 30 months, metachronous upper urinary tract urothelial carcinoma developed in 8 (8.3%) patients and ureteral stenosis in 11 (11.5%) patients. Ureteral stenosis developed in 2 (4.1%) patients who underwent D-J stent placement versus 9 (19.1%) patients who did not, a difference that was significant. Age, tumor diameter, presence of carcinoma in situ (CIS), and bladder tumor progression rate were significantly higher in patients with ureteral stenosis. In multivariate logistic regression analysis, only the presence of CIS was identified as an independent predictor of ureteral stenosis.ConclusionAlthough the rate of ureteral stenosis was significantly lower in patients who underwent ureteral stenting, only the presence of CIS was identified as an independent predictor of ureteral stenosis. Introduction Urothelial carcinoma is the 6th most common tumor type in developed countries. Bladder tumor accounts for 90–95% of these cases. Upper urinary tract urothelial carcinoma (UTUC) is relatively rare, accounting for 5–10% of urothelial tumors [1]. Bladder tumor and UTUC share the same molecular pathogenetic structure, and synchronous or metachronous UTUC may be observed in patients with bladder tumor [2]. While synchronous UTUC is seen in only 1.8% of patients with non-muscle invasive bladder tumor [3], risk factors for metachronous UTUC following bladder tumor diagnosis include high-grade bladder tumor and tumors located in the trigone/orifice [4, 5]. Deep resection of the ureteral orifice may be required in the management of bladder tumors located very close to or involving the ureteral orifice. This procedure increases the risk of ureteral scarring, stenosis, and subsequent upper urinary tract obstruction [6]. Upper urinary tract drainage with retrograde ureteral stenting or percutaneous nephrostomy may be required to treat or prevent obstruction. Percutaneous nephrostomy is more invasive than ureteral stenting and is associated with a higher rate of accidental tube dislodgment and reduced quality of life [7]. Furthermore, ureteral stenting is thought to eliminate the anti-reflux mechanism of the intramural ureter and Waldeyer’s sheath, potentially leading to the transplantation and implantation of tumor cells from the bladder to the upper urinary tract [2]. There are no specific recommendations from the European Association of Urology (EAU) regarding the optimal treatment of this clinical condition [8], and leaving the choice entirely at the discretion of urologists. To our knowledge, factors predicting ureteral stenosis following orifice resection and the efficacy of ureteral stenting in its prevention have not been adequately investigated [6]. Orifice resection performed solely with cutting and selective coagulation for hemostasis may not result in ureteral stenosis. Furthermore, clarifying whether ureteral stenting is effective in preventing ureteral stenosis will be instrumental in clinical decision-making. Given the lack of prospective studies and limited data, especially from small cohorts, this study aims to generate hypothesis-level evidence by evaluating the factors predicting ureteral stenosis following orifice resection and assessing the role of ureteral stenting. Materials and methods This study was conducted in accordance with the Declaration of Helsinki. Following ethics committee approval (Approval Number: 2025/355), the data of patients who underwent bipolar transurethral resection of bladder tumor (TUR-BT) at two tertiary centers between June 2020 and January 2024 were retrospectively reviewed. Patients who underwent orifice resection due to tumor involvement of the ureteral orifice or too close to it were included in the study. Exclusion criteria were muscle-invasive bladder tumor, incomplete TUR-BT, synchronous UTUC, atypical pathology (squamous cell, adenocarcinoma, etc.), patients who did not or could not undergo computed tomography (CT) urography, as well as those with missing follow-up data. In our clinics, perioperative CT urography is routinely performed for tumors located in the trigone/orifice in accordance with EAU guidelines [8]. The presence of synchronous UTUC was evaluated by perioperative CT urography. The following parameters were analyzed: Age, gender, American Society of Anesthesiology (ASA) score, presence of preoperative hydronephrosis, preoperative creatinine and estimated glomerular filtration rate (eGFR), tumor diameter, tumor number (solitary-multiple), tumor stage, tumor grade, presence of carcinoma in-situ (CIS), history of intravesical chemotherapy, follow-up, postoperative creatinine and eGFR, bladder tumor recurrence, bladder tumor progression, metachronous UTUC, and ureteral stenosis. Patients were analyzed by dividing them into two main groups: those who underwent ureteral stenting after TUR-BT and those who did not. Additionally, the cohort was further analyzed based on the development of ureteral stenosis during follow-up: with stenosis and without stenosis. Pathologic staging was performed according to the TNM classification system, and grading according to the WHO 2004 criteria. Risk stratification and the follow-up protocol were conducted in accordance with EAU guidelines [8]. The decision to place a ureteral stent was entirely at the discretion of the primary surgeon. Diagnostic ureterorenoscopy was performed on patients with a ureteral stent during its removal at the first postoperative month. Patients without a ureteral stent were followed up for hydronephrosis using urinary tract ultrasonography (USG) at the first postoperative month. Subsequently, all patients were evaluated for ureteral stenosis at 3 and 6 months using USG, and at 1 year using CT urography. During follow-up, CT urography was performed on patients who indicated hydronephrosis on USG. Patients who demonstrated hydronephrosis on CT urography and had suspicion of ureteral stenosis underwent diagnostic cystoscopy and ureterorenoscopy. Ureteral stenosis was defined as a narrowing that precluded the passage of the ureterorenoscope and where no tumoral lesion was detected at the orifice site. Statistical analysis Data were presented as mean ± standard deviation for normally distributed continuous variables, median (interquartile range) for non-normally distributed continuous variables and frequency (%) for categorical variables. The Kolmogorov-Smirnov test was used to determine the normality of continuous variables. Categorical variables were compared using the Chi-Square test or Fisher’s exact test. Continuous variables were compared using the independent samples t-test or the Mann-Whitney U test. Univariate and multivariate binary logistic regression analyses were performed to evaluate the factors predicting ureteral stenosis. A P value of less than 0.05 was considered significant. Results A total of 96 patients were included in the study. The mean age of the patients was 67.1 ± 10.1 years, and 82.3% of the patients were male. Preoperative hydronephrosis was present in 25 (26%) patients. A D-J stent was inserted in 49 (51%) of the patients after TUR-BT. At a median follow-up of 30 months (12–54 months), metachronous UTUC developed in 8 (8.3%) patients and ureteral stenosis in 11 (11.5%) patients. The median ureteral stenosis development time was 5 months (1–14 months). Age (p = 0.036), ASA score (p = 0.007), and the presence of CIS (p = 0.026) were significantly higher in patients who did not underwent D-J stent placement, whereas the history of intravesical chemotherapy (p = 0.012) was significantly lower in this group. Ureteral stenosis developed in 2 (4.1%) patients who underwent D-J stent placement versus 9 (19.1%) patients who did not, a difference that was significant (p = 0.026). The comparative analysis of patients with and without a ureteral stent following TUR-BT is detailed in Table 1. Table 1Comparison of patients with and without ureteral stenting after TUR-BTD-J Stent (+)D-J Stent (-)(n = 49)(n = 47)p ValueAge (years), Mean ± SD65 ± 8.869.3 ± 11 0.036t Gender, n (%)0.717# Male41 (83.7%)38 (80.9%) Female8 (16.3%)9 (19.1%)ASA Score, n (%)0.007# ASA I-II28 (57.1%)14 (29.8%) ASA III-IV21 (42.9%)33 (70.2%)Preoperative Hydronephrosis, n (%)11 (22.4%)14 (29.8%)0.413#Preoperative Creatinine (mg/dl), Median (IQR)0.9 (0.2)0.9 (0.3)0.665mPreoperative eGFR, Mean ± SD88.8 ± 20.989.4 ± 21.40.895tTumor location0.351f Orifice Involvement45 (91.8%)40 (85.1%) Too close to the orifice4 (8.2%)7 (14.9%)Primary Tumor, n (%)43 (87.8%)36 (76.6%)0.152#Tumor Diameter (mm), Median (IQR)30 (15)35 (20)0.085tNumber of Tumors, n (%)0.714# Single32 (65.3%)29 (61.7%) Multiple17 (34.7%)18 (38.3%)Stage, n (%)0.057 Ta38 (77.6%)28 (59.6%) T111 (22.4%)19 (40.4%)Grade, n (%)0.317# PUNLMP- Low Grade32 (65.3%)26 (55.3%) High Grade17 (34.7%)21 (44.7%)Presence of Carcinoma in Situ, n (%)2 (4.1%)9 (19.1%) 0.026f Follow-up (Months), Median (IQR)24 (18)30 (15)0.055mPostoperative Creatinine (mg/dl), Median (IQR)0.93 (0.19)0.96 (0.14)0.615mPostoperative eGFR, Median (IQR)82.1 (19.8)77.3 (28.4)0.540mIntravesical Chemotherapy, n (%) 0.012f None3 (6.1%)13 (27.7%) Mitomycin C15 (30.6%)8 (17%) BCG31 (63.3%)26 (55.3%)Bladder Tumor Recurrence, n (%)9 (18.4%)14 (29.8%)0.190#Bladder Tumor Progression, n (%)3 (6.1%)7 (14.9%)0.194fMetachronous UTUC, n (%)5 (10.2%)3 (6.4%)0.715fUreteral stenosis, n (%)2 (4.1%)9 (19.1%) 0.026f SD Standard deviation, IQR Interquartile range, ASA American Society of Anesthesiologists, eGFR estimated glomerular filtration rate, PUNLMP papillary urothelial neoplasm of low malignant potential, BCG Bacillus Calmette-Guerin, UTUC Upper tract urothelial carcinomat Independent samples t test, # Chi-square test, m Mann-Whitney u test f Fisher’s exact testBold values indicate statistical significance (p < 0.05) Table 1Comparison of patients with and without ureteral stenting after TUR-BTD-J Stent (+)D-J Stent (-)(n = 49)(n = 47)p ValueAge (years), Mean ± SD65 ± 8.869.3 ± 11 0.036t Gender, n (%)0.717# Male41 (83.7%)38 (80.9%) Female8 (16.3%)9 (19.1%)ASA Score, n (%)0.007# ASA I-II28 (57.1%)14 (29.8%) ASA III-IV21 (42.9%)33 (70.2%)Preoperative Hydronephrosis, n (%)11 (22.4%)14 (29.8%)0.413#Preoperative Creatinine (mg/dl), Median (IQR)0.9 (0.2)0.9 (0.3)0.665mPreoperative eGFR, Mean ± SD88.8 ± 20.989.4 ± 21.40.895tTumor location0.351f Orifice Involvement45 (91.8%)40 (85.1%) Too close to the orifice4 (8.2%)7 (14.9%)Primary Tumor, n (%)43 (87.8%)36 (76.6%)0.152#Tumor Diameter (mm), Median (IQR)30 (15)35 (20)0.085tNumber of Tumors, n (%)0.714# Single32 (65.3%)29 (61.7%) Multiple17 (34.7%)18 (38.3%)Stage, n (%)0.057 Ta38 (77.6%)28 (59.6%) T111 (22.4%)19 (40.4%)Grade, n (%)0.317# PUNLMP- Low Grade32 (65.3%)26 (55.3%) High Grade17 (34.7%)21 (44.7%)Presence of Carcinoma in Situ, n (%)2 (4.1%)9 (19.1%) 0.026f Follow-up (Months), Median (IQR)24 (18)30 (15)0.055mPostoperative Creatinine (mg/dl), Median (IQR)0.93 (0.19)0.96 (0.14)0.615mPostoperative eGFR, Median (IQR)82.1 (19.8)77.3 (28.4)0.540mIntravesical Chemotherapy, n (%) 0.012f None3 (6.1%)13 (27.7%) Mitomycin C15 (30.6%)8 (17%) BCG31 (63.3%)26 (55.3%)Bladder Tumor Recurrence, n (%)9 (18.4%)14 (29.8%)0.190#Bladder Tumor Progression, n (%)3 (6.1%)7 (14.9%)0.194fMetachronous UTUC, n (%)5 (10.2%)3 (6.4%)0.715fUreteral stenosis, n (%)2 (4.1%)9 (19.1%) 0.026f SD Standard deviation, IQR Interquartile range, ASA American Society of Anesthesiologists, eGFR estimated glomerular filtration rate, PUNLMP papillary urothelial neoplasm of low malignant potential, BCG Bacillus Calmette-Guerin, UTUC Upper tract urothelial carcinomat Independent samples t test, # Chi-square test, m Mann-Whitney u test f Fisher’s exact testBold values indicate statistical significance (p < 0.05) Comparison of patients with and without ureteral stenting after TUR-BT SD Standard deviation, IQR Interquartile range, ASA American Society of Anesthesiologists, eGFR estimated glomerular filtration rate, PUNLMP papillary urothelial neoplasm of low malignant potential, BCG Bacillus Calmette-Guerin, UTUC Upper tract urothelial carcinoma t Independent samples t test, # Chi-square test, m Mann-Whitney u test f Fisher’s exact test Bold values indicate statistical significance (p < 0.05) Age (p = 0.028), tumor diameter (p = 0.028), presence of CIS (p < 0.001), and bladder tumor progression rate (p = 0.014) were significantly higher in patients with ureteral stenosis, whereas D-J stent placement (p = 0.026) and postoperative eGFR (p = 0.035) were significantly lower in this group. There was no significant difference in primary/recurrent tumor status, tumor number, stage, or grade between patients with and without ureteral stenosis. Metachronous UTUC was more frequent in patients with ureteral stenosis than in those without, but this difference was not statistically significant (2 patients [18.2%] with ureteral stenosis vs. 6 patients [7.1%] without ureter stenosis, p = 0.228). The comparative analysis of patients with and without ureteral stenosis is shown in Table 2. Among the patients with ureteral stenosis, 3 underwent deobstructive TUR, 2 had D-J stent placement alone, 4 received D-J stent placement combined with balloon dilatation, and 1 underwent robotic ureteroneocystostomy. Laparoscopic radical nephrectomy was performed in 1 patient with a non-functioning hydronephrotic kidney after diagnostic ureterorenoscopy confirmed the absence of tumor. Table 2Comparison of patients with and without ureteral stenosisStenosis (+)Stenosis (-)(n = 11)(n = 85)p ValueAge (years), Mean ± SD73.4 ± 10.566.3 ± 9.9 0.028t Gender, n (%)1.000f Male9 (81.8%)70 (82.4%) Female2 (18.2%)15 (17.6%)ASA Score, n (%)0.106f ASA I-II2 (8.2%)40 (47.1%) ASA III-IV9 (81.8%)45 (52.9%)Preoperative Hydronephrosis, n (%)5 (45.5%)20 (23.5)0.119#Preoperative Creatinine (mg/dl), Mean ± SD0.9 (0.16)0.89 (0.26)0.538mPreoperative eGFR, Mean ± SD84.3 ± 13.189.7 ± 21.80.420tTumor location1.000f Orifice Involvement10 (90.9%)75 (88.2%) Too close to the orifice1 (9.1%)10 (11.8%)Primary Tumor, n (%)7 (63.6%)72 (84.7%)0.101fTumor Diameter (mm), Median (IQR)45 (15)30 (15) 0.028m Number of Tumors, n (%)0.510# Single6 (54.5%)55 (64.7%) Multiple5 (45.5%)30 (35.3%)Stage, n (%)0.280# Ta6 (54.5%)60 (70.6%) T15 (45.5%)25 (29.4%)Grade, n (%)0.106f PUNLMP-Low Grade4 (36.4%)54 (63.5%) High Grade7 (63.6%)31 (36.5%)Presence of Carcinoma in Situ, n (%)5 (45.5%)6 (7.1%) < 0.001# Placement of D-J Stent, n (%)2 (18.2%)47 (55.3%) 0.026f Follow-up (Months), Median (IQR)30 (7.5)30 (18)0.875mPostoperative Creatinine (mg/dl), Median (IQR)0.97 (0.25)0.94 (0.17)0.282mPostoperative eGFR, Median (IQR)74.4 (17.5)85.5 (19.8) 0.035m Intravesical Chemotherapy, n (%)0.145f None4 (36.4%)12 (14.1%) Mitomycin C1 (9.1%)22 (25.9%) BCG6 (54.5%)51 (60%)Bladder Tumor Recurrence, n (%)5 (45.5%)18 (21.2%)0.076#Bladder Tumor Progression, n (%)4 (36.4%)6 (7.1%) 0.014f Metachronous UTUC, n (%)2 (18.2%)6 (7.1%)0.228fSD Standard deviation, IQR Interquartile range, ASA American Society of Anesthesiologists, eGFR estimated glomerular filtration rate, PUNLMP papillary urothelial neoplasm of low malignant potential, BCG Bacillus Calmette-Guerin, UTUC Upper tract urothelial carcinomat Independent samples t test, # Chi-square test, m Mann-Whitney u test f Fisher’s exact testBold values indicate statistical significance (p < 0.05) Table 2Comparison of patients with and without ureteral stenosisStenosis (+)Stenosis (-)(n = 11)(n = 85)p ValueAge (years), Mean ± SD73.4 ± 10.566.3 ± 9.9 0.028t Gender, n (%)1.000f Male9 (81.8%)70 (82.4%) Female2 (18.2%)15 (17.6%)ASA Score, n (%)0.106f ASA I-II2 (8.2%)40 (47.1%) ASA III-IV9 (81.8%)45 (52.9%)Preoperative Hydronephrosis, n (%)5 (45.5%)20 (23.5)0.119#Preoperative Creatinine (mg/dl), Mean ± SD0.9 (0.16)0.89 (0.26)0.538mPreoperative eGFR, Mean ± SD84.3 ± 13.189.7 ± 21.80.420tTumor location1.000f Orifice Involvement10 (90.9%)75 (88.2%) Too close to the orifice1 (9.1%)10 (11.8%)Primary Tumor, n (%)7 (63.6%)72 (84.7%)0.101fTumor Diameter (mm), Median (IQR)45 (15)30 (15) 0.028m Number of Tumors, n (%)0.510# Single6 (54.5%)55 (64.7%) Multiple5 (45.5%)30 (35.3%)Stage, n (%)0.280# Ta6 (54.5%)60 (70.6%) T15 (45.5%)25 (29.4%)Grade, n (%)0.106f PUNLMP-Low Grade4 (36.4%)54 (63.5%) High Grade7 (63.6%)31 (36.5%)Presence of Carcinoma in Situ, n (%)5 (45.5%)6 (7.1%) < 0.001# Placement of D-J Stent, n (%)2 (18.2%)47 (55.3%) 0.026f Follow-up (Months), Median (IQR)30 (7.5)30 (18)0.875mPostoperative Creatinine (mg/dl), Median (IQR)0.97 (0.25)0.94 (0.17)0.282mPostoperative eGFR, Median (IQR)74.4 (17.5)85.5 (19.8) 0.035m Intravesical Chemotherapy, n (%)0.145f None4 (36.4%)12 (14.1%) Mitomycin C1 (9.1%)22 (25.9%) BCG6 (54.5%)51 (60%)Bladder Tumor Recurrence, n (%)5 (45.5%)18 (21.2%)0.076#Bladder Tumor Progression, n (%)4 (36.4%)6 (7.1%) 0.014f Metachronous UTUC, n (%)2 (18.2%)6 (7.1%)0.228fSD Standard deviation, IQR Interquartile range, ASA American Society of Anesthesiologists, eGFR estimated glomerular filtration rate, PUNLMP papillary urothelial neoplasm of low malignant potential, BCG Bacillus Calmette-Guerin, UTUC Upper tract urothelial carcinomat Independent samples t test, # Chi-square test, m Mann-Whitney u test f Fisher’s exact testBold values indicate statistical significance (p < 0.05) Comparison of patients with and without ureteral stenosis SD Standard deviation, IQR Interquartile range, ASA American Society of Anesthesiologists, eGFR estimated glomerular filtration rate, PUNLMP papillary urothelial neoplasm of low malignant potential, BCG Bacillus Calmette-Guerin, UTUC Upper tract urothelial carcinoma t Independent samples t test, # Chi-square test, m Mann-Whitney u test f Fisher’s exact test Bold values indicate statistical significance (p < 0.05) Univariate logistic regression analysis identified age (p = 0.033), tumor diameter (p = 0.040), and presence of CIS (p = 0.001), as predictors significantly increasing the risk of ureteral stenosis, while D-J stent placement was identified as a significant predictor associated with a reduced risk (p = 0.034). Multivariate logistic regression analysis determined that only the presence of CIS was an independent predictor of ureteral stenosis (p = 0.024). The results of the binary logistic regression analysis of factors predicting ureteral stenosis are shown in Table 3. Table 3Univariate and multivariate analysis of factors predicting ureteral stenosisUnivariateMultivariate95% CI95% CIORLowerUpperp ValueORLower Upperp ValueAge1.081.011.157 0.033 1.0670.9831.1580.119Tumor Diameter1.0561.0021.112 0.040 1.0070.9471.0700.831Presence of Carcinoma in Situ10.9722.57846.694 0.001 8.2061.31451.229 0.024 Placement of D-J Stent0.1800.0370.881 0.034 0.3640.0642.0600.253OR Odds ratio, CI Confidence intervalBold values indicate statistical significance (p < 0.05) Table 3Univariate and multivariate analysis of factors predicting ureteral stenosisUnivariateMultivariate95% CI95% CIORLowerUpperp ValueORLower Upperp ValueAge1.081.011.157 0.033 1.0670.9831.1580.119Tumor Diameter1.0561.0021.112 0.040 1.0070.9471.0700.831Presence of Carcinoma in Situ10.9722.57846.694 0.001 8.2061.31451.229 0.024 Placement of D-J Stent0.1800.0370.881 0.034 0.3640.0642.0600.253OR Odds ratio, CI Confidence intervalBold values indicate statistical significance (p < 0.05) Univariate and multivariate analysis of factors predicting ureteral stenosis OR Odds ratio, CI Confidence interval Bold values indicate statistical significance (p < 0.05) Discussion Bladder tumors with ureteral orifice involvement account for 4.8–10.2% of all bladder tumors. However, this issue remains controversial in the literature and has not been sufficiently investigated [4, 6, 9]. The management of bladder tumors with orifice involvement poses a challenge for urologists due to two major potential risks: (1) the potential risk of metachronous UTUC if stenting is performed, and (2) the potential risk of ureteral stenosis if stenting is omitted. Urologists must choose between these two risks based on their clinical experience. Therefore, in this study, we aimed to determine which patients are at risk for ureteral stenosis and to investigate whether ureteral stenting is effective in its prevention. Although we found a significantly lower rate of ureteral stenosis in patients who underwent ureteral stenting, we determined that only the presence of CIS was an independent predictor of ureteral stenosis in multivariate analysis. The effect of urinary drainage (D-J stent or nephrostomy) on the development of metachronous UTUC in bladder tumor patients has frequently been investigated retrospectively, with studies suggesting that ureteral stenting increases this risk [10–12]. Indeed, a recent meta-analysis reported that patients with a D-J stent had a 3-fold higher risk of developing metachronous UTUC compared to patients without a D-J stent (no drainage or nephrostomy) [2]. However, these studies and the meta-analysis were conducted in a more heterogeneous population and most of the patients had advanced disease (pT2-4). Most of the patients requiring ureteral stenting are to relieve obstruction in patients who develop upper urinary tract obstruction, and upper urinary tract obstruction is associated with more advanced stage, worse recurrence-free survival and worse cancer-specific survival [11]. Consequently, the higher rate of metachronous UTUC in these patients compared to those without obstruction may not be entirely related to ureteral stenting itself. Crucially, in the most recent meta-analysis, a subgroup analysis focusing only on patients with hydronephrosis determined that there was no significant difference in metachronous UTUC rates between patients with and without a D-J stent [2]. After electroresection of the orifice, the intramural ureter may shorten, the orifice may dilate and vesicoureteral reflux may develop. There are doubts as to whether this increases the risk of UTUC [4]. De Torres Mateos et al. evaluated 288 superficial bladder tumor patients with voiding cystourethrography 1 month after TUR-BT and found that patients with tumors near the ureteral orifice had significant vesicoureteral reflux compared to other localizations (77% vs. 0%, p < 0.001). They also noted that 15 of 17 patients who subsequently developed metachronous UTUC had refluxive ureters [13]. There is also a concern that ureteral stenting may lead to implantation of tumor cells in the upper urinary tract by eliminating the anti-reflux mechanism [2]. Altok et al. found that bladder tumor patients with orifice involvement had significantly more synchronous and metachronous UTUC compared to other localizations, and no patient with orifice involvement had undergone ureteral stenting [9]. Rodriguez Faba et al. found that ureteral stenting did not predict UTUC recurrence in univariate and multivariate analysis [6]. In the current study, although the metachronous UTUC rate was found to be numerically higher in patients who underwent ureteral stenting, this difference was not significant (5 patients [10.2%] with stent vs. 3 patients [6.4%] without stent, p = 0.715). In studies, the rate of ureteral stenting during TUR-BT of bladder tumors with orifice involvement varies significantly. In a retrospective study of 31 orifice bladder tumors, Chou et al. reported that ureteral stenosis was not detected in any of the 6 patients with D-J stent, while ureteral stenosis was detected in 3 (12%) of 25 patients without D-J stent [4]. In a retrospective study of 112 bladder tumors with orifice involvement by Rodriguez Faba et al., ureteral stenosis developed in 13 patients (11.6%). D-J stents were placed in 36 (31%) of the patients due to extension resection and ureteral stenting did not predict ureteral stenosis in multivariate analysis [6]. In our study, ureteral stenosis developed in 11 patients (11.5%). D-J stents were placed in 49 patients (51%), a rate that was higher compared to the literature. This suggests that concerns regarding the potential risk of ureteral stenosis in the absence of stenting following TUR-BT are more prevalent in our clinics. Although observing a significantly lower rate of ureteral stenosis in patients who underwent D-J stent placement compared to those who did not, our study found that ureteral stenting did not predict ureteral stenosis in multivariate analyses. To our knowledge, Rodriguez Faba et al. are the only researchers who have investigated the factors predicting ureteral stenosis in bladder tumors with orifice involvement. In their multivariate analysis, they found that the primary tumor decreased the risk of ureteral stenosis, and that tumors larger than 1.5 cm and T1 stage were identified as independent predictors of ureteral stenosis [6]. In our study, the primary tumor rate was lower (63.6% vs. 84.7%, p = 0.101) and the T1 stage rate was higher (45.5% vs. 29.4%, p = 0.280) in patients with ureteral stenosis; however, no significant difference was found for either comparison. Similarly, although tumor diameter was significantly higher in patients with ureteral stenosis (45 mm vs. 30 mm, p = 0.028), it was not identified as an independent predictor in the multivariate analysis. Although tumors may have a large diameter, those that are not broad-based (i.e., pedunculated tumors) might have contributed to this result. Therefore, it would be more accurate to determine the width of the tumor base when evaluating the effect of tumor diameter on ureteral stenosis. In the study by Rodriguez Faba et al. although the presence of CIS was significant in univariate analysis, it was not one of the independent factors predicting ureteral stenosis in multivariate analysis [6]. In contrast, we found that only the presence of CIS was an independent factor predicting ureteral stenosis in multivariate analysis. This result may have been caused by the multifocal broad-based nature of CIS and the resulting diffuse inflammation it induces. However, given the limited event count (only 13 cases of ureteral stenosis in Rodriguez Faba et al.‘s study [6] and 11 cases in ours), the findings from both studies should be interpreted with caution. We recognize that we cannot make definitive clinical recommendations based on this small cohort study. However, we believe that our findings will encourage large-volume, multicenter, prospective, and randomized studies. The primary limitations of our study are its retrospective design and the small number of patients. The retrospective design introduces the potential for selection bias. Furthermore, the limited sample size may have affected the statistical significance of certain parameters. Performing logistic regression with only 11 ureteral stenosis events introduces a high risk of model overfitting. Additionally, the non-randomized, discretionary nature of ureteral stenting introduces treatment-selection bias, which is magnified in small cohorts. Another limitation is that tumor size evaluation was based on operative notes and the subjective assessment of the primary surgeon. Conclusion Although the rate of ureteral stenosis was significantly lower in patients who underwent ureteral stenting, only the presence of CIS was identified as an independent predictor of ureteral stenosis. The findings of our study suggest that ureteral stenting may be less effective than expected in preventing ureteral stenosis. However; multicenter, prospective and randomized studies with high volume are needed to obtain more definitive findings.